Retatrutide

Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity.

Obesity is a complex disease that occurs when an individual’s weight is higher than what is considered healthy for his/her height. According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with a BMI of 30 or higher are considered obese.
Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones:
– GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. It stimulates the beta-cells in the pancreas to secrete insulin.
– GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.